Eliquis.
The appellate panel resolved a district court split in the circuit over the reading of federal removal rules, agreeing with the district court that holding to the strict text was appropriate.
March 26, 2019 at 03:00 PM
1 minute read
The original version of this story was published on Newyorklawjournal/newyorklawjournal
In a 21-page order, the U.S. Court of Appeals for the Second Circuit on Tuesday upheld the dismissal of dozens of products liability lawsuits initiated across the country against Bristol‐Myers Squibb Co. and Pfizer Inc. over their blood-thinning medication Eliquis.
The order resolved a split among district courts in the circuit over the proper interpretation of federal forum defendant rules.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
